Archive | October, 2019

Global Family Office BioForum Joins RESI Asia

10 Oct

Interview with Chuck Stetson, CEO of Stetson Family Office

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Click to see part one of a two part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Chuck, who is the third generation running the Stetson Family Office, is an entrepreneur, venture capitalist, and philanthropist. GFOB helps make more high quality investments in the life science arena by connecting regional family offices with regional angel groups, incubators and accelerators – essentially helping family offices around the globe participate in the funding of early stage technology assets located in their local healthcare tech hubs.

This interview, conducted by Dennis Ford, CEO, Life Science Nation and Creator of the Redefining Early Stage Investments (RESI) Conference Series, is a deep dive into how a family office views and participates in funding startups.  Chuck will be representing the GFOB at both RESI Asia events – Shanghai, November 12th and Taipei, November 14th. Click here to register for the events.

FOUR Chances to Present at RESI Asia!

10 Oct

By Gregory Mannix, Vice President International Business Development, LSN

That’s right – RESI Asia will, for the first time, allow participants to present their companies four times over the course of two days. By applying to the Innovation Challenge for RESI Asia, companies will get the chance to present a poster in the exhibition hall AND pitch to a panel of investors at both the Shanghai RESI conference on November 12th and the Taipei RESI conference on November 14th. That is an incredible opportunity to get visibility for your company and meet with many investors and strategics from China, Asia-Pacific and beyond.

We know from experience that companies that compete as finalists in the Innovation Challenge at a RESI conference get more visibility and more one-on-one meetings with investors. The opportunity this November, with two conferences back-to-back in two hot life science hubs in Asia, is UNPRECEDENTED.

As always, participating in the RESI Innovation Challenge carries no additional cost for companies. You’ve got nothing to lose, and everything to gain!

New Healthcare Breakthroughs From All Over the World on Show at RESI Asia

10 Oct

By Lucy Parkinson, VP of Investor Research, LSN

When LSN decided to bring RESI to Asia, we aimed to provide far more than a regional networking hub. Through our relationships with investors and technology hubs worldwide, we knew that many investment firms are looking to Asia as a source of new technologies – and conversely, many investors and major corporations based in Asia want to meet early stage startups from other parts of the world.

Due to the outreach LSN’s team has performed to technology hubs and early stage companies, RESI Asia is building up to a global showcase of early stage drugs, devices, diagnostics, and digital health innovations. We hope you can join us in Shanghai and Taipei to meet these entrepreneurs face to face.

RESI ASIA Therapeutics Companies
RESI ASIA Medical Device Companies
 
RESI ASIA Diagnostics Companies
 
RESI ASIA Digital Health Companies
 
RESI ASIA Service Providers

And More…

Hot Investor Mandate: Opportunistic Cross-Border VC Firm Invests in China and Overseas

10 Oct

A healthcare-focused venture investment fund has investment team members that are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The VC firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The VC firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The VC firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: A CA-Based Angel Group Focused on Life Science Investing

10 Oct

An angel group based in CA makes early-stage equity investments in a wide range of life science companies. The group invests primarily in California, but is open to investing out of state provided a round is being syndicated with a local angel group. The group does not rule out investing outside the USA, but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied, but are usually of about $200,000-$600,000; The group usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

The group is interested in investing in therapeutics (including small molecules, biologics and cell and gene therapies), life science tools, genomics, diagnostics, medical devices, and healthcare IT. The group requires that companies have proof of concept data, such as preclinical test results or a completed prototype of their product; the group does not invest in discovery-stage or pre-prototype companies. The firm is open to investing in any indication or area of technology.

The group prefers to invest in opportunities where an exit is possible in 3-5 years. If outside California, the group requires that companies have built a relationship with an angel group in their local area. For healthcare IT companies, the group favors companies that have already attained revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based PE Interested in Medical Devices and Diagnostics

10 Oct

The China-based PE firm manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC Provides Services for Equity

10 Oct

The corporate VC is the strategic advisory and equity investment arm of a holding company and its CRO affiliate. The firm invests a portion of the normal cost of IND-enabling animal toxicology and pharmacology study services conducted by the CRO in companies and receives equity positions in exchange. The firm seeks to invest in companies located in the U.S. only.

The corporate VC is currently looking for companies developing therapeutics and considers both small molecules and biologics. The firm is open to most therapeutic indications, but generally is not interested in programs in the CNS or respiratory disease spaces. The firm is particularly interested in companies developing new therapies to treat ocular diseases where its CRO affiliate has highly specialized technology and significant expertise.

The firm does not lead investment rounds and acts only as a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →